HLS Therapeutics Inc
TSX:HLS
HLS Therapeutics Inc
Cost of Revenue
HLS Therapeutics Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
HLS Therapeutics Inc
TSX:HLS
|
Cost of Revenue
-$8m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
18%
|
|
M
|
Manitex Capital Inc
XTSX:MNX
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is HLS Therapeutics Inc's Cost of Revenue?
Cost of Revenue
-8m
USD
Based on the financial report for Mar 31, 2024, HLS Therapeutics Inc's Cost of Revenue amounts to -8m USD.
What is HLS Therapeutics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
18%
Over the last year, the Cost of Revenue growth was -45%. The average annual Cost of Revenue growth rates for HLS Therapeutics Inc have been -31% over the past three years , -27% over the past five years , and 18% over the past ten years .